Saxlund Group AB (publ) (STO:SAXG)
Sweden · Delayed Price · Currency is SEK 7.40
-0.40 (-5.13%)
Aug 1, 2025, 4:05 PM CET
CTI BioPharma Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 276.72 | 307.32 | 308.13 | 250.04 | 257.82 | 160.54 | Upgrade | |
Revenue Growth (YoY) | -12.51% | -0.26% | 23.23% | -3.02% | 60.60% | -19.29% | Upgrade |
Cost of Revenue | 184.3 | 217.53 | 236.39 | 170.06 | 177.92 | 106.38 | Upgrade |
Gross Profit | 92.43 | 89.79 | 71.74 | 79.98 | 79.9 | 54.15 | Upgrade |
Selling, General & Admin | 92.49 | 92.49 | 88.11 | 87.17 | 73.03 | 77.78 | Upgrade |
Other Operating Expenses | -0.2 | -0.21 | -0.35 | -0.56 | -2.85 | -3.21 | Upgrade |
Operating Expenses | 96.2 | 96.18 | 91.9 | 90.55 | 73.06 | 77.8 | Upgrade |
Operating Income | -3.77 | -6.39 | -20.16 | -10.58 | 6.84 | -23.65 | Upgrade |
Interest Expense | -4.89 | -6.23 | -6.01 | -3.53 | -1.28 | -4.05 | Upgrade |
Interest & Investment Income | 2.05 | 2.05 | 2.4 | - | 0.09 | - | Upgrade |
Currency Exchange Gain (Loss) | -0.18 | -0.18 | 0.39 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -0 | -0 | -0 | -0.2 | -0.22 | -0.26 | Upgrade |
EBT Excluding Unusual Items | -6.8 | -10.75 | -23.38 | -14.3 | 5.42 | -27.95 | Upgrade |
Pretax Income | -6.8 | -10.75 | -23.38 | -14.3 | 5.42 | -27.95 | Upgrade |
Income Tax Expense | 4.92 | 4.33 | 3.3 | -4.1 | 3.31 | 0.46 | Upgrade |
Earnings From Continuing Operations | -11.71 | -15.07 | -26.68 | -10.21 | 2.12 | -28.41 | Upgrade |
Net Income to Company | - | -15.07 | -26.68 | -10.21 | 2.12 | -28.41 | Upgrade |
Net Income | -11.71 | -15.07 | -26.68 | -10.21 | 2.12 | -28.41 | Upgrade |
Net Income to Common | -11.71 | -15.07 | -26.68 | -10.21 | 2.12 | -28.41 | Upgrade |
Shares Outstanding (Basic) | 7 | 7 | 1 | 1 | 1 | 0 | Upgrade |
Shares Outstanding (Diluted) | 7 | 7 | 1 | 1 | 1 | 0 | Upgrade |
Shares Change (YoY) | 1023.02% | 1022.99% | 0.00% | 2.47% | 56.27% | 29.50% | Upgrade |
EPS (Basic) | -1.63 | -2.09 | -41.61 | -15.92 | 3.38 | -70.97 | Upgrade |
EPS (Diluted) | -1.63 | -2.09 | -41.61 | -20.00 | 3.38 | -70.97 | Upgrade |
Free Cash Flow | -4.79 | -21.75 | -6.83 | -15.69 | -18.58 | -41.55 | Upgrade |
Free Cash Flow Per Share | -0.67 | -3.02 | -10.65 | -24.47 | -29.70 | -103.78 | Upgrade |
Gross Margin | 33.40% | 29.22% | 23.28% | 31.99% | 30.99% | 33.73% | Upgrade |
Operating Margin | -1.36% | -2.08% | -6.54% | -4.23% | 2.65% | -14.73% | Upgrade |
Profit Margin | -4.23% | -4.91% | -8.66% | -4.08% | 0.82% | -17.70% | Upgrade |
Free Cash Flow Margin | -1.73% | -7.08% | -2.22% | -6.28% | -7.21% | -25.88% | Upgrade |
EBITDA | -2.82 | -5.44 | -17.99 | -8.69 | 7.93 | -21.03 | Upgrade |
EBITDA Margin | -1.02% | -1.77% | -5.84% | -3.47% | 3.08% | -13.10% | Upgrade |
D&A For EBITDA | 0.96 | 0.95 | 2.17 | 1.89 | 1.09 | 2.62 | Upgrade |
EBIT | -3.77 | -6.39 | -20.16 | -10.58 | 6.84 | -23.65 | Upgrade |
EBIT Margin | -1.36% | -2.08% | -6.54% | -4.23% | 2.65% | -14.73% | Upgrade |
Effective Tax Rate | - | - | - | - | 60.97% | - | Upgrade |
Revenue as Reported | 276.92 | 307.53 | 308.47 | 250.6 | 260.67 | 163.74 | Upgrade |
Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.